TAIKO PHARMACEUTICAL CO.,LTD. FY2026 Q2 Earnings Report

Quick View

Executive Summary

Although revenue increased in Q2 of FY2026 (the first half), profitability from the core business deteriorated, resulting not in higher operating income but in a substantial decline. Revenue grew to ¥2.64B (¥2.41B in the previous year, YoY +9.3%), but the increase in SG&A expenses offset the benefit of higher revenue, reducing operating income to ¥0.02B (¥0.05B in the previous year, YoY -63.4%). Ordinary income improved to ¥0.04B (YoY +101.4%), supported by non-operating income such as interest income and foreign exchange gains. However, extraordinary income, including gains on the sale of investment securities, recorded in the same period of the previous year (¥0.36B) was absent in the current period, resulting in a substantial decline in net income to ¥0.04B (¥0.28B in the previous year, YoY -84.2%). The key point of this earnings result is that the company’s core profit structure is weakening beneath the revenue increase.

Factors Affecting Performance

【Revenue】Revenue increased to ¥2.64B, up +9.3% year on year. While the core Pharmaceuticals Business led overall performance with revenue of ¥2.52B (+14.4%, composition ratio 95.8%), the Infection Control Business contracted to ¥0.11B (-45.3%, composition ratio 4.2%), resulting in a greater concentration of the business portfolio.

【Profit and Loss】The gross profit margin remained high at 50.8%, but SG&A expenses increased to ¥1.32B (SG&A ratio 50.1%), nearly offsetting the increase in revenue. Segment income in the Pharmaceuticals Business declined to ¥0.56B (-7.3%), while the Infection Control Business continued to report a loss of ¥-0.09B (the loss narrowed by +39.1% year on year), leaving company-wide operating income at only ¥0.02B (YoY -63.4%). Ordinary income improved to ¥0.04B (YoY +101.4%) due to non-operating income, including foreign exchange gains of ¥0.01B, but net income declined to ¥0.04B (YoY -84.2%) due to the absence of extraordinary income recorded in the previous year, including a ¥0.35B gain on the sale of investment securities. The results reflect higher revenue but lower profit, with dilution of the earnings structure emerging as a clear trend.

Segment Analysis

The Pharmaceuticals Business recorded revenue of ¥2.52B (+14.4%), segment income of ¥0.56B (-7.3%), and a profit margin of 22.1%, indicating a slight decline in profitability despite higher revenue. The Infection Control Business recorded revenue of ¥0.11B (-45.3%), a segment loss of ¥-0.09B (the loss narrowed by +39.1% year on year), and a profit margin of -82.9%, demonstrating continued structural losses. The Pharmaceuticals Business accounts for 95.8% of revenue and all segment income, while losses in the Infection Control Business continue to depress the company-wide profit margin. In the Infection Control Business, an impairment loss (an immaterial amount) was recorded for fixed assets for which recoverability was not deemed probable.

Key Financial Metrics

【Profitability】The operating margin declined significantly to 0.6% from the previous year (equivalent to 190bp), while the net profit margin remained at only 1.7%. ROE was 0.5%, primarily due to the decline in the net profit margin, while total asset turnover of 0.238x and financial leverage of 1.32x remained broadly stable.【Cash Quality】Operating Cash Flow (OCF) was ¥-0.07B, below net income of ¥0.04B, indicating challenges in cash generation.【Investment Efficiency】Capital expenditures were ¥0.18B, and free cash flow was ¥-0.75B, indicating that cash generation remained below investment and shareholder returns.【Financial Soundness】The equity ratio remained high at 76.0%, and short-term solvency was strong, with current assets of ¥7.20B compared with current liabilities of ¥1.40B. Cash and deposits decreased substantially year on year to ¥2.67B, primarily due to repayment of long-term borrowings (financing CF ¥-0.85B).

Cash Flow Analysis

Operating CF was ¥-0.07B, remaining below net income of ¥0.04B. An increase in inventories (¥-0.29B) and a decrease in the provision for bonuses pressured operating CF, while a decrease in trade receivables (¥+0.53B) contributed positively. Investing CF was ¥-0.68B, including capital expenditures of ¥0.18B and a transfer to time deposits (¥0.50B). Financing CF was ¥-0.85B, primarily due to repayment of long-term borrowings (¥0.67B). As a result, free cash flow (operating CF + investing CF) was ¥-0.75B, and cash and deposits declined to ¥2.67B. Cash generation from operating activities has not kept pace with improvements in earnings, making inventory and working capital management a challenge from a funding-efficiency perspective.

Quality of Earnings

There were no extraordinary gains or losses in the current period, and the absence of extraordinary income of ¥0.36B, including the ¥0.35B gain on the sale of investment securities recorded in the same period of the previous year, made the year-on-year decline in net income appear substantial. Non-operating income was ¥0.03B, equivalent to approximately 1% of revenue, and primarily consisted of interest income and foreign exchange gains. Accordingly, the relative contribution of the ¥0.01B foreign exchange gain was significant compared with operating income of ¥0.02B. Operating CF was below net income, indicating a gap between reported earnings and actual cash generation, primarily due to working capital factors such as the increase in inventories. The difference between ordinary income and net income was small, and the impact of tax effects was limited.

Earnings Forecasts and Guidance

Progress against the full-year plan (revenue of ¥7.20B, operating income of ¥0.50B, and ordinary income of ¥0.52B) was 36.6% for revenue, 3.4% for operating income, and 7.9% for ordinary income in the first half. Compared with a simple 50% time-apportionment benchmark, all figures were below target, with the delays in operating income and ordinary income particularly pronounced. The company has not revised either its earnings forecast or dividend forecast, and the plan assumes back-half-weighted progress, including the containment of SG&A expenses and a reduction in losses in the Infection Control Business during the second half.

Shareholder Returns

The interim dividend at the end of Q2 was zero. The full-year dividend forecast is ¥3.5 per share. Based on the full-year net income forecast of ¥0.55B and the average number of shares outstanding during the period (approximately 50.28M shares), the annual total dividend is calculated at approximately ¥0.18B, implying a payout ratio of approximately 32%. The dividend forecast has not been revised. Given that current free cash flow is ¥-0.75B, cash generation during the second half will be a key factor in assessing the company’s ability to execute its annual dividend plan.

Risk Factors

1. Business Portfolio Concentration Risk: The Pharmaceuticals Business accounts for 95.8% of revenue, indicating a high degree of dependence on a single business. The Infection Control Business has contracted to revenue of ¥0.11B (-45.3% year on year), while its segment loss of ¥-0.09B continues.

2. Weak Cash Generation: Operating CF of ¥-0.07B was below net income of ¥0.04B, and free cash flow was negative at ¥-0.75B. Deterioration in working capital, including the increase in inventories, is pressuring cash flow.

3. Dilution of Profitability: The operating margin declined to 0.6%, with the increase in SG&A expenses offsetting the benefit of higher revenue. An impairment loss (an immaterial amount) was also recorded on fixed assets in the Infection Control Business.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (pharma)

Profitability and Returns

Although median data for the industry was not obtained, the company’s operating margin of 0.6% and net profit margin of 1.7% appear to be at the low end relative to typical pharmaceutical companies.

Growth and Capital Efficiency

The revenue growth rate of 9.3% indicates a trend of increasing revenue, but comparison with profit margins suggests that growth has not translated into earnings.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Despite higher revenue, the operating margin declined to 0.6%, with the increase in SG&A expenses offsetting the benefit of higher revenue. Continued losses in the Infection Control Business are also depressing overall profitability.

2. Operating CF was below net income, and free cash flow was negative. Working capital movements, centered on the increase in inventories, created a gap between reported earnings and cash generation.

3. First-half progress against the full-year plan was 36.6% for revenue and 3.4% for operating income, with the delay in operating income particularly significant. The company has not revised its earnings forecast, and the extent to which profitability improves in the second half will be a key point to monitor in future earnings results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥151–¥159 at cost of equity ±1%, and ¥155–¥155 at ω±0.1.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest Rate Reference Month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q2 showed a return to a small operating profit, but underlying earnings conversion weakened materially despite 9.3% revenue growth. Revenue increased to ¥2.636bn, led by the Pharmaceuticals business, while operating income declined 63.4% year on year to only ¥17m. The operating margin compressed by 126bp to 0.6% from 1.9% in the prior-year period. Gross margin fell by approximately 393bp to 50.8%, indicating that the increase in cost of sales materially outpaced revenue growth. SG&A rose 3.8% to ¥1.321bn, slower than revenue growth, but its ratio to sales still increased by approximately 253bp because the gross-margin decline was larger. Ordinary income doubled to ¥41m, supported by ¥27m of non-operating income, including ¥12m of interest income and ¥10m of foreign-exchange gains. Consequently, ordinary income exceeded operating income by a wide margin, showing that reported below-the-line profitability was not principally generated by the core operation. Net income was ¥44m, down 84.1% year on year, principally because the comparable period included a ¥347m gain on sale of investment securities. The current period's negative ¥4m tax expense created a tax benefit, lifting net income above ¥40m profit before tax; this effect is not a recurring operating earnings driver. Operating cash flow was negative ¥66m while net income was positive ¥44m, resulting in an OCF/net-income ratio of negative 1.50x and weak cash realization. Free cash flow was negative ¥751m, reflecting negative operating cash flow and ¥184m of capital expenditure, together with substantial investing cash outflows. The balance sheet remains conservatively capitalized, with a 512.7% current ratio, 480.0% quick ratio, and 0.32x debt-to-equity ratio. Cash declined ¥1.589bn from the prior-year period to ¥2.666bn, although ¥500m was placed into time deposits and short-term investment securities were ¥500m at period end. Pharmaceuticals is the core business, accounting for 95.7% of segment revenue and generating segment profit of ¥557m, whereas Infection Control remained loss-making. Full-year sales guidance of ¥7.2bn implies Q2 sales progress of 36.6%, below the standard 50% midpoint, while operating-profit progress was only 3.4% against the ¥500m target. The key implication is that management must achieve a pronounced second-half recovery in gross margin and corporate-cost absorption to meet unchanged full-year guidance. Liquidity provides time for that recovery, but the current earnings profile has low operating efficiency and weak cash conversion.

Profitability Analysis

The reported annualized DuPont ROE is 1.0%, decomposed into a 1.7% net profit margin, 0.475x annualized asset turnover, and 1.32x financial leverage. The principal constraint is profitability rather than leverage: the 0.6% EBIT margin and 1.7% net margin are both well below conventional return thresholds. Financial leverage is modest and therefore neither meaningfully enhances returns nor creates balance-sheet stress. Revenue growth did not translate into operating-profit growth because gross profit increased only ¥19m to ¥1.339bn while SG&A rose ¥48m to ¥1.321bn. Gross margin declined to 50.8% from approximately 54.7% in the prior-year period, the largest adverse change in the earnings structure. Although SG&A grew more slowly than revenue, SG&A consumed 50.1% of sales versus approximately 52.8% a year earlier; the operating-margin pressure therefore originated primarily in gross-profit deterioration rather than uncontrolled overhead expansion. EBITDA was ¥165m and the EBITDA margin was 6.3%, higher than the EBIT margin because depreciation and amortization was ¥148m, but still modest for the asset base. Capex/depreciation was 1.24x, indicating reinvestment modestly above depreciation; it is not yet producing satisfactory annualized ROIC of 0.6%. Interest coverage of 17.0x and EBITDA interest coverage of 165.0x show that interest cost is immaterial to the weak EBIT margin. The five-factor DuPont tax burden of 1.10 reflects the interim tax benefit and should not be interpreted as a structurally favorable cash-tax rate. The interest burden of 2.353 is elevated because non-operating income, particularly interest and FX gains, exceeded the small EBIT base; it does not represent a recurring financing advantage. Pharmaceuticals segment profit fell 7.3% to ¥557m despite sales increasing 14.4% to ¥2.523bn, suggesting reduced segment margin. Infection Control sales declined 45.3% to ¥111m and its segment loss narrowed to ¥92m from ¥151m, while Other businesses recorded a ¥14m loss. Unallocated corporate costs increased to ¥433m from ¥396m, offsetting the aggregate segment profit of ¥450m and leaving consolidated operating profit at ¥17m. Sustainable improvement requires restoration of gross margin, continued narrowing of Infection Control losses, and better absorption or reduction of corporate costs.

Growth Assessment

Top-line momentum was positive, with consolidated revenue up 9.3% year on year to ¥2.636bn. Growth was concentrated in Pharmaceuticals, where sales increased ¥317m year on year to ¥2.523bn. This segment remains the core business by a substantial margin, representing 95.7% of consolidated revenue and supplying all positive segment profit. Infection Control's revenue contraction of ¥92m reduced its scale to 4.2% of consolidated sales, although the smaller operating loss is a favorable directional development. Revenue growth quality is constrained by the sharp gross-margin decline and the inability to convert higher sales into higher operating profit. The year-on-year net-income decline is also affected by the absence of the prior-period ¥347m securities-sale gain, so it should not be read solely as a deterioration in recurring operations. Full-year guidance calls for ¥7.2bn in sales, ¥500m in operating income, ¥520m in ordinary income, and ¥550m in net income. Q2 cumulative progress is 36.6% for sales, 3.4% for operating income, 7.9% for ordinary income, and 8.0% for net income, all below the standard 50% midpoint, with profit progress lagging particularly sharply. The unchanged forecast therefore embeds a heavily back-end-loaded earnings recovery, including an operating margin expansion from 0.6% in the first half to a level sufficient to deliver a 6.9% full-year operating margin. No forecast revision was announced. For a company classified in pharmaceuticals, the disclosed operating profile is better assessed through its established Pharmaceuticals business and consumer/healthcare demand dynamics; the available figures do not evidence R&D-led pipeline monetization. The main growth test is whether Pharmaceuticals sales can retain momentum while recovering product profitability and whether Infection Control can reduce losses without renewed revenue deterioration.

Financial Health

Financial health is strong from a liquidity and solvency perspective. Current assets of ¥7.198bn exceeded current liabilities of ¥1.404bn by ¥5.794bn, producing a 512.7% current ratio and a 480.0% quick ratio. These ratios indicate no current maturity mismatch risk. Total equity was ¥8.425bn, equal to 76.0% of total assets, while total liabilities were only ¥2.666bn. The debt-to-equity ratio of 0.32x is conservative and well below the 2.0x level associated with aggressive debt financing. Current portions of long-term loans were ¥119m, and repayments of long-term loans were ¥673m during the half year, reducing near-term refinancing dependence. Cash and deposits fell 37.4% year on year to ¥2.666bn, but the liquidity interpretation should include ¥500m of short-term investment securities and the ¥500m placement into time deposits in investing cash flow. Inventories increased 48.5% to ¥459m, while accounts payable increased 36.2% to ¥365m. The inventory increase requires monitoring because the quality alerts identify both high inventory days and a high work-in-process mix, even though headline liquidity remains ample. Net defined-benefit liability of ¥638m is the largest identified noncurrent liability and represents a continuing long-term obligation. Property, plant and equipment totaled ¥3.354bn, or 30.2% of assets, reflecting a tangible-asset base that requires adequate utilization and returns. Asset retirement obligations were ¥20m and are not material relative to equity. No material goodwill-related balance-sheet exposure is indicated, and intangible assets were only ¥36m, or 0.3% of total assets.

Notable B/S Changes

Cash and deposits: -¥1.589bn (-37.4%) to ¥2.666bn - cash declined following negative operating cash flow, ¥500m of time-deposit placement, capital expenditure, debt repayment, and dividend payments; liquidity nevertheless remains strong. Inventories: +¥150m (+48.5%) to ¥459m - inventory accumulation is consistent with elevated inventory-day and cash-conversion-cycle alerts, increasing cash lock-up and potential obsolescence risk. Accounts payable: +¥97m (+36.2%) to ¥365m - supplier financing increased, partially supporting working capital, although other payables declined materially in the cash-flow bridge. Current liabilities: -¥1.105bn (-44.0%) to ¥1.404bn - principally consistent with a reduction in current portions of long-term loans, strengthening short-term liquidity. Total assets: -¥1.179bn (-9.6%) to ¥11.091bn - the decline was led by lower cash, while total equity decreased only ¥93m to ¥8.425bn, lifting the capital adequacy ratio to 76.0% from 69.4%.

Cash Flow Quality

Cash-flow quality was weak in the first half. Operating cash flow was negative ¥66m versus positive net income of ¥44m, yielding an OCF/net-income ratio of negative 1.50x, well below the 0.8x warning threshold. Cash conversion, measured as OCF/EBITDA, was negative 0.40x, confirming that the ¥165m EBITDA did not convert into operating cash. The principal working-capital outflow was a ¥286m increase in inventories. Other significant operating-cash outflows included a ¥296m decrease in other payables, a ¥132m reduction in bonus provisions, and an ¥85m consumption-tax-related outflow. A ¥534m reduction in trade receivables partly offset these items, but did not restore positive operating cash flow. The provided 1.0% accruals ratio is low in absolute terms, but the direct OCF/net-income divergence remains the more important near-term earnings-quality signal. The 134-day DSO alert is high against the 60-day benchmark and indicates slow cash collection relative to sales; this increases sensitivity to customer payment timing even though receivables declined during the period. The 268-day inventory-days alert signals a large inventory commitment relative to cost of sales and elevates inventory valuation, obsolescence, and production-planning risk. The separately reported 65-day inventory-days alert is also above its 60-day benchmark; together with the 268-day measure, it indicates that both finished-goods-focused and broader inventory-basis measures warrant monitoring. The 350-day cash conversion cycle materially exceeds the 120-day benchmark, tying up cash in the operating cycle and reducing the reliability of accounting earnings as a source of distributable cash. Work in process was ¥868m and represented 45.6% of manufacturing inventory under the provided alert, above the 40% threshold; this points to a prolonged production cycle and increases execution risk around conversion into saleable products. Free cash flow was negative ¥751m, so internally generated cash did not cover capital expenditure or other investing commitments. Investing cash flow was negative ¥685m, including ¥500m of payments into time deposits and ¥184m of PPE purchases. Financing cash flow was negative ¥853m, including ¥673m of long-term debt repayment and ¥165m of cash dividends paid. The ¥1.589bn net decrease in cash was therefore driven by a combination of weak operating conversion, reinvestment and financial outflows, rather than an immediate liquidity shortfall.

Dividend Sustainability

No Q2 dividend was declared, while the full-year forecast calls for DPS of ¥3.50. Based on forecast EPS of ¥10.95, the implied dividend-only payout ratio is approximately 32.0%, below the 60% sustainability benchmark. This planned payout is modest relative to book value per share of ¥167.47 and total equity of ¥8.425bn. However, first-half free cash flow was negative ¥751m, so dividend coverage by internally generated cash was not achieved in the reported period. Cash dividends paid were ¥165m in the half year, demonstrating that cash distributions continued despite negative operating cash flow. The company can fund the planned distribution from its strong liquid-asset base in the near term, but sustained dividend capacity should ultimately depend on a recovery in operating cash conversion rather than balance-sheet cash deployment. The unchanged dividend outlook is consistent with management maintaining its policy, but forecast achievement is important because first-half net income of ¥44m represents only 8.0% of the ¥550m full-year profit target.

Risk Assessment

Business risks include Margin recovery risk: consolidated EBIT margin was only 0.6%, down from approximately 1.9% a year earlier, despite revenue growth. A further inability to recover gross margin would make the full-year ¥500m operating-profit target difficult to attain., Pharmaceuticals concentration: the Pharmaceuticals business generated 95.7% of sales and ¥557m of segment profit. Performance deterioration in this core business would have a direct group-level effect., Infection Control turnaround risk: segment revenue fell 45.3% to ¥111m and the segment remained loss-making at ¥92m. Although the loss narrowed, sustained demand weakness or fixed-cost underabsorption could delay profitability., Inventory and production-cycle risk: high inventory-day alerts, a 45.6% work-in-process ratio, and a 350-day cash conversion cycle indicate exposure to inventory obsolescence, demand-forecasting errors, manufacturing scheduling, and cash lock-up., FX sensitivity: ¥10m of FX gains represented 58.8% of operating profit. Given the very small operating-profit base, currency movements can materially affect reported ordinary earnings..

Financial risks include Earnings-to-cash divergence: OCF was negative ¥66m against ¥44m of net income, and cash conversion was negative 0.40x. Continued divergence would pressure cash resources and distribution capacity., Receivable-collection risk: the 134-day DSO alert is well above the 60-day reference point, increasing working-capital and counterparty-payment sensitivity., Forecast execution risk: operating-profit progress was 3.4% and net-profit progress 8.0% at Q2, versus a standard 50% midpoint. The unchanged guidance assumes substantial second-half profitability improvement., Cash-balance decline: cash and deposits declined ¥1.589bn year on year to ¥2.666bn, although liquidity ratios and additional short-term investments remain strong..

Key concerns include Low operating efficiency is the highest-priority concern: annualized ROIC was 0.6% and annualized ROE was 1.0%, both indicating inadequate returns on the capital employed., The quality of reported ordinary income is limited because non-operating income of ¥27m exceeded EBIT of ¥17m; interest and FX gains contributed materially to earnings., Prior-year net income included a ¥347m gain on sale of investment securities, making year-on-year net-income comparisons less representative of recurring performance., The balance sheet materially mitigates immediate financial distress risk, but it does not eliminate the need for operating-margin and cash-conversion recovery..

Investment Implications

Key takeaways include Revenue growth is positive and Pharmaceuticals remains a profitable core business, but first-half profitability deteriorated sharply at the consolidated level., Gross-margin restoration and control of unallocated corporate costs are the central earnings levers., The strong liquidity position and conservative 0.32x debt-to-equity ratio provide financial flexibility during the recovery period., Negative operating cash flow, extended cash conversion, and high inventory-related alerts weaken the quality of the first-half earnings outcome., Unchanged full-year guidance requires a significant second-half acceleration in operating income and cash generation..

Metrics to watch include Consolidated gross margin and EBIT margin, Pharmaceuticals segment sales growth and segment-profit margin, Infection Control segment loss and revenue trajectory, Unallocated corporate costs relative to revenue, Operating cash flow, OCF/EBITDA cash conversion, and free cash flow, DSO, inventory days, work-in-process ratio, and cash conversion cycle, Progress toward full-year operating income guidance of ¥500m, Cash and deposits, short-term investments, and debt repayments.

Regarding relative positioning, Relative to standard profitability benchmarks, the company is weak on operating margin, annualized ROE, and annualized ROIC, but strong on liquidity, capitalization, and interest-servicing capacity. Its current profile is that of a financially resilient company whose valuation-relevant operating outcome depends on whether core Pharmaceuticals can convert sales growth into gross-profit and cash-flow recovery.